Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Participant Flow Report for NCT03421379

Raw xml | Download


<Composition xmlns="http://hl7.org/fhir">
  <id value="399871"/>
  <meta>
    <versionId value="5"/>
    <lastUpdated value="2025-12-11T20:35:21.032Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-report"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><p class="res-header-id"><b>Generated Narrative: Composition 399871</b></p><a name="399871"> </a><a name="hc399871"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-report.html">ParticipantFlowReport</a></p></div><p><b>url</b>: <a href="https://fevir.net/resources/Composition/399871">https://fevir.net/resources/Composition/399871</a></p><p><b>identifier</b>: FEvIR Object Identifier/399871, FEvIR Linking Identifier/NCT03421379-participant-flow-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowReport}">Participant Flow Report</span></p><p><b>date</b>: 2025-12-11 20:35:21+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Participant Flow Report for NCT03421379</p><p><b>custodian</b>: <a href="Organization-118079.html">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style="display: none">*</td><td>Cite As</td><td><div><p>Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json.</p>
</div></td></tr></table><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Group #FG000</b></p><a name="399871/FG000"> </a><a name="hc399871/FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-exposure-group.html">ExposureGroup</a></p></div><p><b>name</b>: NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride</p><p><b>description</b>: </p><div><p>A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2.</p>
</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><h3>Characteristics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Research Study from which this is a flow group</span></td><td>NCT03421379</td><td>false</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Group #FG001</b></p><a name="399871/FG001"> </a><a name="hc399871/FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-exposure-group.html">ExposureGroup</a></p></div><p><b>name</b>: NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder</p><p><b>description</b>: </p><div><p>A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2.</p>
</div><p><b>type</b>: Person</p><p><b>membership</b>: Enumerated</p><h3>Characteristics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td><td><b>Exclude</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:">Research Study from which this is a flow group</span></td><td>NCT03421379</td><td>false</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG000</b></p><a name="399871/NCT03421379-flow-milestone-0-Period-1-group-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-0-Period-1-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>34</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-1-group-FG001</b></p><a name="399871/NCT03421379-flow-milestone-0-Period-1-group-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-0-Period-1-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>41</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG000</b></p><a name="399871/NCT03421379-flow-milestone-1-Period-1-group-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-1-Period-1-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Received at Least One Dose of Study Drug at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>33</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-1-group-FG001</b></p><a name="399871/NCT03421379-flow-milestone-1-Period-1-group-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-1-Period-1-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Received at Least One Dose of Study Drug at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>39</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG000</b></p><a name="399871/NCT03421379-flow-milestone-2-Period-1-group-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-2-Period-1-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-1-group-FG001</b></p><a name="399871/NCT03421379-flow-milestone-2-Period-1-group-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-2-Period-1-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG000</b></p><a name="399871/NCT03421379-flow-milestone-3-Period-1-group-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-3-Period-1-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>2</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-3-Period-1-group-FG001</b></p><a name="399871/NCT03421379-flow-milestone-3-Period-1-group-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-3-Period-1-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-3-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 1</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>4</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG000</b></p><a name="399871/NCT03421379-flow-reason-Period-1-group-FG000"> </a><a name="hc399871/NCT03421379-flow-reason-Period-1-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Reasons for withdraw at Period 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></p><p><b>category</b>: <span title="Codes:">Withdrawal by Subject</span></p><p><b>quantity</b>: 0</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></p><p><b>category</b>: <span title="Codes:">Physician Decision</span></p><p><b>quantity</b>: 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></p><p><b>category</b>: <span title="Codes:">Did not receive treatment</span></p><p><b>quantity</b>: 1</p></blockquote></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-reason-Period-1-group-FG001</b></p><a name="399871/NCT03421379-flow-reason-Period-1-group-FG001"> </a><a name="hc399871/NCT03421379-flow-reason-Period-1-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-reason-Period-1-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: Reasons for withdraw at Period 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></p><p><b>category</b>: <span title="Codes:">Withdrawal by Subject</span></p><p><b>quantity</b>: 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></p><p><b>category</b>: <span title="Codes:">Physician Decision</span></p><p><b>quantity</b>: 1</p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></p><p><b>category</b>: <span title="Codes:">Did not receive treatment</span></p><p><b>quantity</b>: 2</p></blockquote></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000</b></p><a name="399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001</b></p><a name="399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000</b></p><a name="399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001</b></p><a name="399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000</b></p><a name="399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>0</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001</b></p><a name="399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Washout Period (3 to 14 Days)</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>0</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG000</b></p><a name="399871/NCT03421379-flow-milestone-0-Period-2-group-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-0-Period-2-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 2</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-0-Period-2-group-FG001</b></p><a name="399871/NCT03421379-flow-milestone-0-Period-2-group-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-0-Period-2-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-0-Period-2-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: STARTED at Period 2</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG000</b></p><a name="399871/NCT03421379-flow-milestone-1-Period-2-group-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-1-Period-2-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>32</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-1-Period-2-group-FG001</b></p><a name="399871/NCT03421379-flow-milestone-1-Period-2-group-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-1-Period-2-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-1-Period-2-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>37</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG000</b></p><a name="399871/NCT03421379-flow-milestone-2-Period-2-group-FG000"> </a><a name="hc399871/NCT03421379-flow-milestone-2-Period-2-group-FG000"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG000</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG000">Glucagon Nasal Powder/Glucagon Hydrochloride</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>0</td></tr></table></blockquote><hr/><blockquote><p class="res-header-id"><b>Generated Narrative: Evidence #NCT03421379-flow-milestone-2-Period-2-group-FG001</b></p><a name="399871/NCT03421379-flow-milestone-2-Period-2-group-FG001"> </a><a name="hc399871/NCT03421379-flow-milestone-2-Period-2-group-FG001"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-participant-flow-evidence.html">ParticipantFlowEvidence</a></p></div><p><b>identifier</b>: FEvIR Linking Identifier/NCT03421379-flow-milestone-2-Period-2-group-FG001</p><p><b>title</b>: ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter: </p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td><a href="CodeSystem-179423.html#179423-evidence-communication">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title="Codes:{https://fevir.net/resources/CodeSystem/179423 ParticipantFlowEvidence}">ParticipantFlowEvidence</span></td></tr></table><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href="#hc399871/FG001">Glucagon Hydrochloride Solution/Glucagon Nasal Powder</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: NOT COMPLETED at Period 2</p></blockquote><h3>Statistics</h3><table class="grid"><tr><td style="display: none">-</td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{https://fevir.net/sevco STATO:0000047}">Count</span></td><td>0</td></tr></table></blockquote></div>
  </text>
  <contained>
    <Group>
      <id value="FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"/>
      </meta>
      <name
            value="NCT03421379 Flow Group Glucagon Nasal Powder/Glucagon Hydrochloride"/>
      <description
                   value="A single dose of 3 milligram (mg) glucagon nasal powder was administered intranasally in period 1 then 1 mg single dose intramuscular glucagon hydrochloride solution was administered in period 2."/>
      <type value="person"/>
      <membership value="enumerated"/>
      <characteristic>
        <code>
          <text value="Research Study from which this is a flow group"/>
        </code>
        <valueReference>
          <display value="NCT03421379"/>
        </valueReference>
        <exclude value="false"/>
      </characteristic>
    </Group>
  </contained>
  <contained>
    <Group>
      <id value="FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"/>
      </meta>
      <name
            value="NCT03421379 Flow Group Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
      <description
                   value="A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM) in period 1 then 3 mg single dose glucagon nasal powder was administered in period 2."/>
      <type value="person"/>
      <membership value="enumerated"/>
      <characteristic>
        <code>
          <text value="Research Study from which this is a flow group"/>
        </code>
        <valueReference>
          <display value="NCT03421379"/>
        </valueReference>
        <exclude value="false"/>
      </characteristic>
    </Group>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-0-Period-1-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-0-Period-1-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="STARTED at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="34"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-0-Period-1-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-0-Period-1-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="STARTED at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="41"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-1-Period-1-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-1-Period-1-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display
                   value="Received at Least One Dose of Study Drug at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="33"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-1-Period-1-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-1-Period-1-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display
                   value="Received at Least One Dose of Study Drug at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="39"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-2-Period-1-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-2-Period-1-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="COMPLETED at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="32"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-2-Period-1-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-2-Period-1-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="COMPLETED at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="37"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-3-Period-1-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-3-Period-1-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="NOT COMPLETED at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="2"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-3-Period-1-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-3-Period-1-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="NOT COMPLETED at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="4"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-reason-Period-1-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-reason-Period-1-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="Reasons for withdraw at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <category>
          <text value="Withdrawal by Subject"/>
        </category>
        <quantity>
          <value value="0"/>
        </quantity>
      </statistic>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <category>
          <text value="Physician Decision"/>
        </category>
        <quantity>
          <value value="1"/>
        </quantity>
      </statistic>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <category>
          <text value="Did not receive treatment"/>
        </category>
        <quantity>
          <value value="1"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-reason-Period-1-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-reason-Period-1-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="Reasons for withdraw at Period 1"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <category>
          <text value="Withdrawal by Subject"/>
        </category>
        <quantity>
          <value value="1"/>
        </quantity>
      </statistic>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <category>
          <text value="Physician Decision"/>
        </category>
        <quantity>
          <value value="1"/>
        </quantity>
      </statistic>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <category>
          <text value="Did not receive treatment"/>
        </category>
        <quantity>
          <value value="2"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id
          value="NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value
               value="NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="STARTED at Washout Period (3 to 14 Days)"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="32"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id
          value="NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value
               value="NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="STARTED at Washout Period (3 to 14 Days)"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="37"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id
          value="NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value
               value="NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="COMPLETED at Washout Period (3 to 14 Days)"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="32"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id
          value="NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value
               value="NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="COMPLETED at Washout Period (3 to 14 Days)"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="37"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id
          value="NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value
               value="NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="NOT COMPLETED at Washout Period (3 to 14 Days)"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="0"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id
          value="NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value
               value="NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="NOT COMPLETED at Washout Period (3 to 14 Days)"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="0"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-0-Period-2-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-0-Period-2-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="STARTED at Period 2"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="32"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-0-Period-2-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-0-Period-2-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="STARTED at Period 2"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="37"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-1-Period-2-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-1-Period-2-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="COMPLETED at Period 2"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="32"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-1-Period-2-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-1-Period-2-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="COMPLETED at Period 2"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="37"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-2-Period-2-group-FG000"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-2-Period-2-group-FG000"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG000"/>
          <type value="Group"/>
          <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="NOT COMPLETED at Period 2"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="0"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <contained>
    <Evidence>
      <id value="NCT03421379-flow-milestone-2-Period-2-group-FG001"/>
      <meta>
        <profile
                 value="http://hl7.org/fhir/uv/ebm/StructureDefinition/participant-flow-evidence"/>
      </meta>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="NCT03421379-flow-milestone-2-Period-2-group-FG001"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <title
             value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2"/>
      <status value="active"/>
      <author>
        <name
              value="Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter"/>
      </author>
      <useContext>
        <code>
          <system value="https://fevir.net/resources/CodeSystem/179423"/>
          <code value="evidence-communication"/>
          <display value="Evidence Communication"/>
        </code>
        <valueCodeableConcept>
          <coding>
            <system value="https://fevir.net/resources/CodeSystem/179423"/>
            <code value="ParticipantFlowEvidence"/>
            <display value="ParticipantFlowEvidence"/>
          </coding>
        </valueCodeableConcept>
      </useContext>
      <variableDefinition>
        <variableRole value="population"/>
        <observed>
          <reference value="#FG001"/>
          <type value="Group"/>
          <display
                   value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
        </observed>
      </variableDefinition>
      <variableDefinition>
        <variableRole value="outcome"/>
        <observed>
          <display value="NOT COMPLETED at Period 2"/>
        </observed>
      </variableDefinition>
      <statistic>
        <statisticType>
          <coding>
            <system value="https://fevir.net/sevco"/>
            <code value="STATO:0000047"/>
            <display value="Count"/>
          </coding>
        </statisticType>
        <quantity>
          <value value="0"/>
        </quantity>
      </statistic>
    </Evidence>
  </contained>
  <url value="https://fevir.net/resources/Composition/399871"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="399871"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value value="NCT03421379-participant-flow-report"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <status value="final"/>
  <type>
    <coding>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="ParticipantFlowReport"/>
      <display value="ParticipantFlowReport"/>
    </coding>
    <text value="Participant Flow Report"/>
  </type>
  <date value="2025-12-11T20:35:21.032Z"/>
  <author>
    <display value="[No author listed.]"/>
  </author>
  <title value="Participant Flow Report for NCT03421379"/>
  <custodian>🔗 
    <reference value="Organization/118079"/>
    <type value="Organization"/>
    <display value="Computable Publishing LLC"/>
  </custodian>
  <relatesTo>
    <type value="cite-as"/>
    <targetMarkdown
                    value="Participant Flow Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399871. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399871. Computable resource at: https://fevir.net/resources/Composition/399871#json."/>
  </relatesTo>
  <section>
    <title value="Flow PreAssignment Details"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="participant-flow-details"/>
        <display value="Participant Flow Details"/>
      </coding>
      <text value="FlowPreAssignmentDetails"/>
    </code>
    <text>
      <status value="generated"/>
      <div xmlns="http://www.w3.org/1999/xhtml">Participants were randomized to receive either nasal glucagon or intramuscular (IM) glucagon in the first period, followed by the alternate treatment in the second period.</div>
    </text>
  </section>
  <section>
    <title value="Flow Group List"/>
    <code>
      <text value="FlowGroupList"/>
    </code>
    <text>
      <status value="generated"/>
      <div xmlns="http://www.w3.org/1999/xhtml">Glucagon Nasal Powder/Glucagon Hydrochloride, Glucagon Hydrochloride Solution/Glucagon Nasal Powder</div>
    </text>
    <entry>
      <reference value="#FG000"/>
      <type value="Group"/>
      <display value="Glucagon Nasal Powder/Glucagon Hydrochloride"/>
    </entry>
    <entry>
      <reference value="#FG001"/>
      <type value="Group"/>
      <display value="Glucagon Hydrochloride Solution/Glucagon Nasal Powder"/>
    </entry>
  </section>
  <section>
    <title value="STARTED at Period 1"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="STARTED at Period 1"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-milestone-0-Period-1-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 1"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-milestone-0-Period-1-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 1"/>
    </entry>
  </section>
  <section>
    <title value="Received at Least One Dose of Study Drug at Period 1"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="Received at Least One Dose of Study Drug at Period 1"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-milestone-1-Period-1-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Received at Least One Dose of Study Drug at Period 1"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-milestone-1-Period-1-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Received at Least One Dose of Study Drug at Period 1"/>
    </entry>
  </section>
  <section>
    <title value="COMPLETED at Period 1"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="COMPLETED at Period 1"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-milestone-2-Period-1-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 1"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-milestone-2-Period-1-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 1"/>
    </entry>
  </section>
  <section>
    <title value="NOT COMPLETED at Period 1"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="NOT COMPLETED at Period 1"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-milestone-3-Period-1-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 1"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-milestone-3-Period-1-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 1"/>
    </entry>
  </section>
  <section>
    <title value="Reasons for withdraw at Period 1"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="Reasons for withdraw at Period 1"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-reason-Period-1-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - Reasons for withdraw at Period 1"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-reason-Period-1-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - Reasons for withdraw at Period 1"/>
    </entry>
  </section>
  <section>
    <title value="STARTED at Washout Period (3 to 14 Days)"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="STARTED at Washout Period (3 to 14 Days)"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference
                 value="#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Washout Period (3 to 14 Days)"/>
    </entry>
    <entry>
      <reference
                 value="#NCT03421379-flow-milestone-0-Washout-Period--OPEN---3-to-1-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Washout Period (3 to 14 Days)"/>
    </entry>
  </section>
  <section>
    <title value="COMPLETED at Washout Period (3 to 14 Days)"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="COMPLETED at Washout Period (3 to 14 Days)"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference
                 value="#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Washout Period (3 to 14 Days)"/>
    </entry>
    <entry>
      <reference
                 value="#NCT03421379-flow-milestone-1-Washout-Period--OPEN---3-to-1-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Washout Period (3 to 14 Days)"/>
    </entry>
  </section>
  <section>
    <title value="NOT COMPLETED at Washout Period (3 to 14 Days)"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="NOT COMPLETED at Washout Period (3 to 14 Days)"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference
                 value="#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Washout Period (3 to 14 Days)"/>
    </entry>
    <entry>
      <reference
                 value="#NCT03421379-flow-milestone-2-Washout-Period--OPEN---3-to-1-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Washout Period (3 to 14 Days)"/>
    </entry>
  </section>
  <section>
    <title value="STARTED at Period 2"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="STARTED at Period 2"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-milestone-0-Period-2-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - STARTED at Period 2"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-milestone-0-Period-2-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - STARTED at Period 2"/>
    </entry>
  </section>
  <section>
    <title value="COMPLETED at Period 2"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="COMPLETED at Period 2"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-milestone-1-Period-2-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - COMPLETED at Period 2"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-milestone-1-Period-2-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - COMPLETED at Period 2"/>
    </entry>
  </section>
  <section>
    <title value="NOT COMPLETED at Period 2"/>
    <code>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="results"/>
        <display value="Results"/>
      </coding>
      <text value="Participant Flow Results"/>
    </code>
    <focus>
      <display value="NOT COMPLETED at Period 2"/>
    </focus>
    <text>
      <status value="empty"/>
      <div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
    </text>
    <entry>
      <reference value="#NCT03421379-flow-milestone-2-Period-2-group-FG000"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Nasal Powder/Glucagon Hydrochloride - NOT COMPLETED at Period 2"/>
    </entry>
    <entry>
      <reference value="#NCT03421379-flow-milestone-2-Period-2-group-FG001"/>
      <type value="Evidence"/>
      <display
               value="ParticipantFlowEvidence: NCT03421379 Glucagon Hydrochloride Solution/Glucagon Nasal Powder - NOT COMPLETED at Period 2"/>
    </entry>
  </section>
</Composition>